Positive 6-month safety data of P2a study of Cx611 in rheumatoid arthritis Read more…
NYSE Euronext: TIG ’s cGMP inspection by the Dutch authorities has Read more…
The independent Safety Monitoring Board has approved further dosing Read more…
Go-ahead from the independent Safety Monitoring Board based on safety data Read more…
TiGenix (NYSE Euronext: TIG) has moved into the randomized stage of the P2a clinical trial in rheumatoid arthritis.
Founder and Director of Research, Henry McCusker enters his tenth (10) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.
I started this blog to add commentary, update news flow and insightful opinions that are intelligent, fit to print and SEC compliant.